Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4

Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
Medtronic Says PulseSelect Ablation System Demonstrates ‘Impressive Results’ – Medtronic (NYSE:MDT) – Stocks to Watch
  • Sat. May 4th, 2024

Medtronic Says PulseSelect Ablation System Demonstrates ‘Impressive Results’ – Medtronic (NYSE:MDT)

ByVandana Singh

Mar 6, 2023
Medtronic Says PulseSelect Ablation System Demonstrates 'Impressive Results' - Medtronic (NYSE:MDT)

[ad_1]

  • Medtronic plc MDT announced that its PulseSelect Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse event rate of 0.7%, one of the lowest adverse event rates of any prior FDA Investigational Device Exemption (IDE) trial for atrial fibrillation (AF) ablation or any multi-center PFA study. 
  • PULSED AF exceeded the threshold for its efficacy performance goal, and further, clinical success, freedom from recurrence of any symptomatic atrial arrhythmias, was at least 80% for each patient cohort. 
  • PFA is an ablation technology that uses pulsed electric fields to isolate the pulmonary veins for patients with paroxysmal or persistent AF.
  • There were no esophageal events, pulmonary vein stenosis, or phrenic nerve injury.
  • PULSED AF exceeded the threshold for efficacy performance at 66% efficacy in paroxysmal AF patients and 55% in persistent AF patients, based on the pre-specified performance goals of >50% (paroxysmal) and >40% (persistent) at 12 months. 
  • Freedom from atrial arrhythmia recurrence at 12 months was 70% in the paroxysmal cohort and 62% in the persistent. Additionally, clinical success, freedom from recurrence of any symptomatic atrial arrhythmias, was 80% for paroxysmal and 81% for the persistent cohort.
  • Price Action: MDT shares are down 1.86% at $81.84 on the last check Monday.

[ad_2]

Image and article originally from www.benzinga.com. Read the original article here.